Jump to content

Talk:Pegfilgrastim

Page contents not supported in other languages.
From Wikipedia, the free encyclopedia

Cost of Neulasta

[edit]

Cancer patients (and their insurance) pays an average of $3,000+ per shot, where one shot is administered for each chemo treatment. It would be nice to add a section in this article explaining why the cost is so high (without being political). When was the drug patented and when will the patent expire? Is it expensive to manufacture? — Preceding unsigned comment added by Ttwiv (talk • contribs) 00:30, 28 May 2011 (UTC)[reply]

I am a cancer patient who will be given this med soon. IMO, there is no way to explain the high price without getting political. As a proud part of U.S. capitalism, pharmaceutical companies charge what the market will bear. Developing a new med that ~80% of cancer chemotherapy patients absolutely require to meet their chemotherapy timetable doesn't happen often, so they squeeze whatever they can get. Whether this is ethical and fair, and balanced against their general development and other overhead costs is an open question, since there is no transparency and little regulation, and they lobby to keep it that way. David Spector (talk) 00:26, 16 November 2016 (UTC)[reply]

India trade names

[edit]

can you add India trade names. 65.175.243.206 (talk) 21:46, 13 September 2015 (UTC)[reply]

Biosimilars

[edit]

The Pegfilgrastim § Biosimilars section does not seem to be of any use. There is no value in specifying when all of the various biosimilar forms were approved by various agencies. Barring any dissent I am going to remove this whole section. Kimen8 (talk) 23:14, 29 January 2024 (UTC)[reply]

It's been some time and WP:SILENCE is consensus. I'm removing this section. Kimen8 (talk) 17:50, 21 March 2024 (UTC)[reply]
The contents have been put here in in case someone wishes to restore at some point in the future without digging through the history:
Extended content
See also: Biosimilars

Ristempa was approved for medical use in Australia in January 2017.[1][2]

Tezmota was approved for medical use in Australia in March 2018.[3]

Pegfilgrastim-jmdb (Fulphila) was approved for medical use in the United States in June 2018.[4][5]

Fulphila was approved for medical use in Australia in August 2018.[6][7][8]

Pelgraz was approved for medical use in the European Union in September 2018.[9]

Udenyca was approved for medical use in the European Union in September 2018.[10]

On 2 November 2018, Coherus Biosciences received FDA approval for its biosimilar, pegfilgrastim-cbqv (Udenyca). The push to receive approval and begin production of Udenyca was due in large part to the quickly increasing cost of Neulasta, which has nearly tripled since its release in 2002.[11][12]

Pelmeg was approved for medical use in the European Union in November 2018.[13]

Fulphila was approved for medical use in the European Union in November 2018.[14]

Ziextenzo was approved for medical use in the European Union in November 2018.[15]

Fulphila was approved for medical use in Canada in December 2018.[16]

Grasustek was approved for medical use in the European Union in June 2019.[17]

Ziextenzo was approved for medical use in Australia in July 2019.[18][19][20][21]

Pelgraz was approved for medical use in Australia in August 2019.[22][23][24]

Lapelga and Neutropeg were approved for medical use in Australia in August 2019.[19][25][26]

Pegfilgrastim-bmez (Ziextenzo) was approved for medical use in the United States in November 2019.[27][28]

Cegfila was approved for medical use in the European Union in December 2019.[29]

Ziextenzo was approved for medical use in Canada in April 2020.[30]

Pegfilgrastim-apgf (Nyvepria) was approved for medical use in the United States in June 2020.[31][32] Nyvepria was approved for medical use in the European Union in November 2020.[33]

Nyvepria was approved for medical use in Canada in October 2020.[34]

Stimufend was approved for medical use in the European Union in March 2022.[35][36]

Pegfilgrastim-pbbk (Fylnetra) was approved for medical use in the United States in May 2022.[37][38]

Pegfilgrastim-fpgk (Stimufend) was approved for medical use in the United States in September 2022.[39]

References

  1. ^ "TGA eBS - Product and Consumer Medicine Information Licence". Archived from the original on 29 September 2022. Retrieved 20 February 2022.
  2. ^ "Ristempa". NPS MedicineWise. 15 July 2021. Archived from the original on 29 September 2022. Retrieved 19 February 2022.
  3. ^ "Tezmota". NPS MedicineWise. 15 July 2021. Archived from the original on 29 September 2022. Retrieved 19 February 2022.
  4. ^ "FDA approves first biosimilar to Neulasta to help reduce the risk of infection during cancer treatment". U.S. Food and Drug Administration (Press release). 4 June 2018. Archived from the original on 11 June 2020. Retrieved 11 June 2020.
  5. ^ "Drug Approval Package: Fulphila". U.S. Food and Drug Administration (FDA). 26 October 2018. Archived from the original on 11 June 2020. Retrieved 11 June 2020.
  6. ^ "Fulphila". NPS MedicineWise. 15 July 2021. Archived from the original on 29 September 2022. Retrieved 19 February 2022.
  7. ^ "Prescription medicines: registration of new generic medicines and biosimilar medicines, 2018". Therapeutic Goods Administration (TGA). 28 February 2019. Archived from the original on 20 February 2022. Retrieved 19 February 2022.{{cite web}}: CS1 maint: unfit URL (link)
  8. ^ "AusPAR: Pegfilgrastim | Therapeutic Goods Administration (TGA)". Archived from the original on 18 December 2022. Retrieved 18 December 2022.
  9. ^ "Pelgraz EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 30 December 2019. Retrieved 2 April 2020.
  10. ^ "Udenyca EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 11 June 2020. Retrieved 2 April 2020.
  11. ^ "FDA Approves Coherus' Pegfilgrastim Biosimilar, Udenyca". 2 November 2018. Archived from the original on 14 March 2020. Retrieved 26 February 2019.
  12. ^ "Drug Approval Package: Udenyca". U.S. Food and Drug Administration (FDA). 5 March 2019. Archived from the original on 18 December 2019. Retrieved 11 June 2020.
  13. ^ "Pelmeg EPAR". European Medicines Agency (EMA). 24 September 2018. Archived from the original on 11 June 2020. Retrieved 2 April 2020.
  14. ^ "Fulphila EPAR". European Medicines Agency (EMA). 24 September 2018. Archived from the original on 11 June 2020. Retrieved 2 April 2020.
  15. ^ "Ziextenzo EPAR". European Medicines Agency (EMA). 24 September 2018. Archived from the original on 11 June 2020. Retrieved 2 April 2020.
  16. ^ "Summary Basis of Decision (SBD) for Fulphila". Health Canada. 23 October 2014. Archived from the original on 31 May 2022. Retrieved 29 May 2022.
  17. ^ "Grasustek EPAR". European Medicines Agency (EMA). 24 April 2019. Archived from the original on 11 June 2020. Retrieved 2 April 2020.
  18. ^ "Ziextenzo". Therapeutic Goods Administration (TGA). 13 December 2019. Archived from the original on 20 October 2021. Retrieved 25 August 2020.
  19. ^ a b "Prescription medicines: registration of new generic medicines and biosimilar medicines, 2019". Therapeutic Goods Administration (TGA). 10 January 2020. Archived from the original on 20 February 2022. Retrieved 19 February 2022.{{cite web}}: CS1 maint: unfit URL (link)
  20. ^ "Ziextenzo". NPS MedicineWise. 15 July 2021. Archived from the original on 20 February 2022. Retrieved 19 February 2022.
  21. ^ "Ziextenzo | Therapeutic Goods Administration (TGA)". Archived from the original on 18 December 2022. Retrieved 18 December 2022.
  22. ^ "TGA eBS - Product and Consumer Medicine Information Licence". Archived from the original on 20 February 2022. Retrieved 20 February 2022.
  23. ^ "Pelgraz". NPS MedicineWise. 15 July 2021. Archived from the original on 20 February 2022. Retrieved 19 February 2022.
  24. ^ "PELGRAZ pegfilgrastim 6 mg/0.6 mL solution for injection pre-filled syringe (308177) | Therapeutic Goods Administration (TGA)". Archived from the original on 18 December 2022. Retrieved 18 December 2022.
  25. ^ "Prescription medicines registrations | Therapeutic Goods Administration (TGA)". Archived from the original on 18 December 2022. Retrieved 18 December 2022.
  26. ^ "LAPELGA, NEUTROPEG (Apotex Pty LTD) | Therapeutic Goods Administration (TGA)". Archived from the original on 18 December 2022. Retrieved 18 December 2022.
  27. ^ "Ziextenzo". U.S. Food and Drug Administration (FDA). Archived from the original on 11 June 2020. Retrieved 17 December 2019.
  28. ^ "Drug Approval Package: Ziextenzo". U.S. Food and Drug Administration (FDA). 27 December 2019. Archived from the original on 11 June 2020. Retrieved 11 June 2020.
  29. ^ "Cegfila EPAR". European Medicines Agency (EMA). Archived from the original on 11 June 2020. Retrieved 2 April 2020.
  30. ^ "Summary Basis of Decision (SBD) for Ziextenzo". Health Canada. 23 October 2014. Archived from the original on 30 May 2022. Retrieved 29 May 2022.
  31. ^ "Nyvepria". U.S. Food and Drug Administration (FDA). Archived from the original on 11 June 2020. Retrieved 11 June 2020.
  32. ^ "Drug Approval Package: Nyvepria". U.S. Food and Drug Administration (FDA). 11 August 2020. Archived from the original on 25 January 2021. Retrieved 26 May 2022.
  33. ^ "Nyvepria EPAR". European Medicines Agency (EMA). Archived from the original on 24 July 2021. Retrieved 11 October 2021.
  34. ^ "Summary Basis of Decision (SBD) for Nyvepria". Health Canada. 23 October 2014. Archived from the original on 30 May 2022. Retrieved 29 May 2022.
  35. ^ "Stimufend EPAR". European Medicines Agency (EMA). Archived from the original on 21 April 2022. Retrieved 4 April 2022.
  36. ^ "Stimufend Product information". Union Register of medicinal products. Archived from the original on 4 March 2023. Retrieved 3 March 2023.
  37. ^ "Drug Approval Package: Fylnetra". U.S. Food and Drug Administration (FDA). 15 July 2022. Archived from the original on 3 September 2022. Retrieved 2 September 2022.
  38. ^ "Fylnetra- pegfilgrastim injection". DailyMed. 26 May 2022. Archived from the original on 3 July 2022. Retrieved 19 June 2022.
  39. ^ "Stimufend- pegflilgrastim-fpgk injection, solution". DailyMed. 15 September 2022. Archived from the original on 21 January 2023. Retrieved 21 January 2023.

Kimen8 (talk) 17:59, 21 March 2024 (UTC)[reply]

Retrieved from "https://en.wikipedia.org/w/index.php?title=Talk:Pegfilgrastim&oldid=1214867815"